Concomitant therapy for multiple sclerosis

Neurology

Volumn 63, Issue 11 SUPPL. 5, 2004, Pages

  Stuart, William H ^a   Vermersch, Patrick ^b  

^a Peachtree Neurological Clinic   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ESTRIOL; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PENTOXIFYLLINE; PREDNISONE; RITUXIMAB; SIMVASTATIN;

AMENORRHEA; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; INFERTILITY; LONG TERM CARE; MULTIPLE SCLEROSIS; MYELOID LEUKEMIA; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

EID: 10344229910     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.63.11_suppl_5.s28     Document Type: Review

References (76)

1. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146.
2. Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis. A systematic review. Arch Intern Med 2002;162:2161-2169.
3. National Multiple Sclerosis Society. Early Intervention (Disease Management Consensus Statement). Available at http://www.nationalmssociety.org/ Sourcebook-Early.asp. Accessed February 2004.
4. Kaufman M. Combining therapies with interferon beta for relapsing and early progressive MS: a review. Int J MS Care 2002;4:50-65.
5. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-1460.
6. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE Trial. Neurology 2002;59:1496-1506.
7. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
8. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 2002;59:1507-1517.
9. Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002;73:148-153.
10. Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon β-1a and interferon β-1b in MS patients are cross-reactive. Neurology 1998;51:1698-1702.
11. Weiner HL. A 21 point unifying hypothesis on the etiology and treatment of multiple sclerosis. Can J Neurol Sci 1998;25:93-101.
12. Confavreux C. Combination therapies. In: Rudick RA, Goodkin DE, eds. Multiple sclerosis therapeutics. London: Martin Dunitz, 1999:395-403.
13. Dhib-Jalbut S, Chen M, Henschel K, et al. Effect of combined IFNβ-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Mult Scler 2002;8:485-491.
14. Zang YCQ, Hong J, Robinson RR, et al. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. Neurology 2003;60(suppl 1):A394-395. Abstract.
15. Zang Y, Hong J, Robinson R, et al. Immune regulatory properties and interactions of copolymer-1 and beta-interferon 1a in multiple sclerosis. J Neuroimmunol 2003;137:144-153.
16. Dhib-Jalbut S, Chen M, Costello K, Panitch H. Effect of combined IFNβ-1a and glatiramer acetate (GA) therapy on GA-T-cell responses in MS. Neurology 2001;56(suppl 3):A225-226. Abstract.
17. Lublin F, Cutter G, Elfont R, et al. A trial to assess the safety of combining therapy with interferon beta-1a and glatiramer acetate in patients with relapsing MS. Neurology 2001;56(suppl):A148. Abstract.
18. Lublin F, Baier M, Cutter G, et al. Results of the extension of a trial to assess the longer term safety of combining interferon beta-1a and glatiramer acetate. Neurology 2002;58(suppl 3):A85. Abstract.
19. Novantrone® (mitoxantrone for injection concentrate) prescribing information; Serono Inc., Rockland, MA; April 2003.
20. Hartung H-P, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025.
21. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118.
22. Food and Drug Administration. FDA approves Novantrone for treating advanced multiple sclerosis. Available at: http://www.fda.gov/bbs/topics/ answers/ans01046.html. Accessed November 2003.
23. Jeffery DR, Durden DD, Burdette JH. Pilot trial of interferon β-1b and mitoxantrone in multiple sclerosis using monthly gadolinium-enhanced MRI. Neurology 2001;56(suppl 3):A353. Abstract.
24. Jeffery DR, Chepuri NB, Rosenburg J. Safety and efficacy of combination therapy with interferon beta-1b and mitoxantrone in worsening multiple sclerosis using monthly gadolinium-enhanced MRI. Neurology 2002;56(suppl 3):A167. Abstract.
25. Le Page E, Leray E, Debouverie M, et al. Induction treatment with mitoxantrone in worsening relapsing remitting multiple sclerosis: a "rescue therapy" for sub-optimal responders to interferon beta? A pilot study. Neurology 2003;60(suppl 1):A149. Abstract.
26. Miller H, Newell DJ, Ridley A. Multiple sclerosis. Trials of maintenance treatment with prednisolone and soluble aspirin. Lancet 1961;1:127-129.
27. Miller H, Newell DJ, Ridley A. Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (A.C.T.H.). Lancet 1961;2:1120-1122.
28. Buckley C, Kennard C, Swash M. Treatment of acute exacerbations of multiple sclerosis with intravenous methylprednisolone. J Neurol Neurosurg Psychiatry 1982;45:179-180.
29. Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986;36:238-243.
30. Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991;41:1219-1222.
31. Miller DH, Thompson AJ, Morrissey SP, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992;55:450-453.
32. Thompson AJ, Kennard C, Swash, M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989;39:969-971.
33. Noseworthy JH, Gold R, Hartung H-P. Treatment of multiple sclerosis: recent trials and future perspectives. Curr Opin Neurol 1999;12:279-293.
34. Gasperini C, Pozzilli C, Bastianello S, et al. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. Neurology 1998;50:403-406.
35. Rao AB, Richert N, Howard T, et al. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNβ-1b. Neurology 2002;59:688-694.
36. Salama HH, Kolar OJ, Zang YCQ, Zhang J. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with MS. Neurology 2002;58(suppl 3):A307. Abstract.
37. Hommes OR, Prick JJG, Lamers KJB. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg 1975;78:59-72.
38. Gobbini MI, Smith ME, Richert ND, Frank JA, McFarland HF. Effect of open-label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol 1999;99:142-149.
39. Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337:441-446.
40. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993;43:910-918.
41. Weinstock-Guttman B, Kinkel RP, Cohen JA, Ransohoff RR, Rudick RA. Treatment of "transitional MS" with cyclophosphamide and methylprednisolone (CTX/MP) followed by interferon β. Neurology 1997;48(suppl 2):A341. Abstract.
42. Patti F, Cataldi ML, Nicoletti F, et al. Combination of cyclophosphamide and interferon-β halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;71:404-407.
43. Patti F, Reggio E, Fiorilla T, et al. Rapidly transitional multiple sclerosis patients treated with combination of cyclophosphamide and interferon beta: follow-up 36 months after discontinuation of therapy. Neurology 2003;60(suppl 1):A148-149. Abstract.
44. Kaufman M, Norton J, Sonnenfeld G. Safety and tolerability of the combination of interferon beta-1a and oral cyclophosphamide for patients with multiple sclerosis. Neurology 2001;56(suppl 3):A354. Abstract.
45. Smith DR, Weinstock-Guttman B, Cohen JA, et al. Design of randomized, blinded, MRI trial of pulse cyclophosphamide rescue therapy in B-IFN resistant active MS. Neurology 2001;56(suppl 3):A356. Abstract.
46. Smith DR, Weinstock-Guttman B, Cohen JA, et al. Randomized trial of pulse cyclophosphamide in IFN-β resistant active MS. Neurology 2002;58(suppl 3):A455. Abstract.
47. Smith DR, Weinstock-Guttman B, Cohen JA, et al. Blinded, randomized trial of pulse cyclophosphamide in IFN B resistant active MS. Neurology 2003;60(suppl 1):A84. Abstract.
48. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338:1051-1055.
49. Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet 1997;350:261.
50. Kolar OJ, Huler KKH, Muckway MA. Continuous combined immunomodulatory- immunosuppressive (IMIS) therapy in multiple sclerosis (MS). Mult Scler 1999;5(suppl 1):S95. Abstract.
51. Moreau T, Blanc S, Riche G, Confavreux C. Erazimus: combination of azathioprine and beta-interferon in multiple sclerosis: results of a pilot safety study. Mult Scler 1999;5(suppl 1):S95. Abstract.
52. Moreau T, Blanc S, Riche G, Nony P, Confavreux C. A pilot safety and tolerability study of interferon beta 1a in combination with azathioprine in multiple sclerosis. Neurology 2001;56(suppl 3):A353. Abstract.
53. Fernández O, Guerrero M, Mayorga C, et al. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. J Neurol 2002;249:1058-1062.
54. Goodkin DE, Rudick RA, VanderBrug Medendorp S. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37:30-40.
55. Chungi VS, Bourne DWA, Dittert LW. Drug absorption VIII: kinetics of GI absorption of methotrexate. J Pharm Sci 1978;67:560-561.
56. Bertino JR, Kamen B, Romanini A. Folate antagonists. In: Holland, Bast, Morton Frei, et al, eds. Cancer medicine. 4th ed. Baltimore, MD: Williams & Wilkins, 1997:907-922.
57. Calabresi PA, Wilterdink JL, Rogg JM, et al. An open-label trial of combination therapy with interferon β-1a and oral methotrexate in MS. Neurology 2002;58:314-317.
58. Rowe VD, Wang D, John HA, et al. Rescue therapy with high dose intravenous methotrexate in MS patients worsening despite Avonex therapy. Neurology 2003;60(suppl 1):A149-150. Abstract.
59. Cohen JA, Calabresi PA, Fisher E, et al. Rationale and design of the Avonex Combination Trial. Mult Scler 2003;9(suppl 1):S139. Abstract.
60. Vermersch P, Waucquier N, Bourteel H, et al. Combination of interferon beta-1a (Avonex) and mycophenolate mofetil (Cellcept) phase II trial in relapsing-remitting multiple sclerosis. Mult Scler 2003;9(suppl 1):18. Abstract.
61. Elices MJ. BX-471 Berlex. Curr Opin Investig Drugs 2002;3:865-869.
62. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
63. Vollmer T, Phillips JT, Goodman A, et al. Safety, pharmacokinetic (PK), and pharmacodynamic (PD) drug interaction study of antegren and interferon beta-1A (IFN β-1a, Avonex) in patients with relapsing remitting multiple sclerosis. Rev Neurologique 2000(suppl 3):S127. Abstract.
64. Weber F, Polak T, Günther A, et al. Synergistic immunomodulatory effects of interferon-β1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol 1998;44:27-34.
65. Qu ZX, Dayal A, Jensen MA, Arnason BG. All-trans retinoic acid potentiates the ability of interferon beta-1b to augment suppressor cell function in multiple sclerosis. Arch Neurol 1998;55(3):315-321.
66. Havrdova E, Horakova D, Krasensky J, et al. Interferon beta-1a in combination with azathioprine and low-dose steroids for relapsing-remitting multiple sclerosis: preliminary clinical and MRI data from a two-year, double-blind, randomized, placebo-controlled study. Neurology 2002;58(suppl 3):A457. Abstract.
67. Rudick RA, Sandrock A, Panzara M, Polman C. Study designs of two phase III trials to determine the safety and efficacy of natalizumab (Antegren®) alone and when added to Interferon beta 1a (Avonex®) in patients with relapsing-remitting multiple sclerosis. Neurology 2003;60(suppl):A479. Abstract.
68. Rudick RA, Calabresi P, Confavreux C, et al. Baseline patient characteristics of the SENTINEL study: a study designed to determine the efficacy and safety of natalizumab (Antegren) in combination with interferon beta-1a (Avonex) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Mult Scler 2003;9 (suppl 1):S141-142. Abstract.
69. National Multiple Sclerosis Society. Agents in clinical trials for MS. Fall 2003. Available at: http://www.nationalmssociety.org/pdf/research/agents. pdf. Accessed November 2003.
70. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration. Minocycline as a potential therapy for multiple sclerosis. Brain 2002;125:1297-1308.
71. Stüve O, Youssef S, Steinman L, Zamvil SS. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 2003;16:393-401.
72. Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002;52:421-428.
73. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000;27(suppl 12):99-103.
74. Chou YK, Morrison WJ, Weinberg AD, et al. Immunity to TCR peptides in multiple sclerosis. II. T cell recognition of Vβ5.2 and Vβ6.1 CDR2 peptides. J Immunol 1994;152:2520-2529.
75. Correale J, Lund B, McMillan M, et al. T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol 2000;107:130-139.
76. Muraro PA, Ingoni RC, Martin R. Hematopoietic stem cell transplantation for multiple sclerosis: current status and future challenges. Curr Opin Neurol 2003;16:299-305.